Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Thursday, 21 March 2013
AstraZeneca appoints Marc Dunoyer as Executive Vice President, Global Portfolio & Product Strategy AstraZeneca today announced that Marc Dunoyer is to join the company in the newly created role of Executive Vice President, Global Portfolio & Product Strategy.
Thursday, 21 March 2013
AstraZeneca and Karolinska Institutet to create Integrated Translational Research Centre AstraZeneca and the Swedish medical university Karolinska Institutet announced today their intention to create an Integrated Translational Research Centre for cardiovascular and metabolic disease and regenerative medicine located at Karolinska Institutet’s site in Stockholm, Sweden.
Thursday, 21 March 2013
AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.
Download our brochure

Download your comprehensive guide to partnering with us.


Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar